Semin Thromb Hemost 2008; 34(2): 147-153
DOI: 10.1055/s-2008-1079254
© Thieme Medical Publishers

Tissue Factor and Protease-Activated Receptor Signaling in Cancer

Florence Schaffner1 , 3 , Wolfram Ruf2 , 3
  • 1Research Associate
  • 2Professor
  • 3Department of Immunology, The Scripps Research Institute, La Jolla, California
Further Information

Publication History

Publication Date:
21 July 2008 (online)

ABSTRACT

The activation of the coagulation cascade in the tumor microenvironment is a key feature of advanced malignancies. On tumor cells, tissue factor (TF) plays a central role to initiate cross-talk through the release of procoagulant microparticles or through direct, protease-activated receptor (PAR)-mediated cell signaling that leads to the production of soluble cytokines and angiogenic growth factors. In addition, the hemostatic system in the host compartment sustains crucial circuits that promote metastasis and support tumor growth and angiogenesis. Experimental tumor and genetic models have defined specific pathways that are supported by tumor cell and host TF and have identified potential therapeutic modalities to specifically interrupt TF signaling in tumor biology without impairment of hemostatic functions.

REFERENCES

  • 1 Rickles F R, Patierno S, Fernandez P M. Tissue factor, thrombin, and cancer.  Chest. 2003;  124(3 Suppl) 58S-68S
  • 2 Clauss M, Gerlach M, Gerlach H et al.. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.  J Exp Med. 1990;  172 1535-1545
  • 3 Shoji M, Hancock W W, Abe K et al.. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.  Am J Pathol. 1998;  152 399-411
  • 4 Ruf W, Mueller B M. Thrombin generation and the pathogenesis of cancer.  Semin Thromb Hemost. 2006;  32(Suppl 1) 61-68
  • 5 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.  N Engl J Med. 2000;  342 1953-1958
  • 6 Dvorak H F, Quay S C, Orenstein N S et al.. Tumor shedding and coagulation.  Science. 1981;  212 923-924
  • 7 Hron G, Kollars M, Weber H et al.. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.  Thromb Haemost. 2007;  97 119-123
  • 8 Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms.  Blood. 2007;  110 1723-1729
  • 9 Chand H S, Ness S A, Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells.  Int J Cancer. 2006;  118 1713-1720
  • 10 Bogdanov V Y, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.  Nat Med. 2003;  9 458-462
  • 11 Bogdanov V Y, Kirk R I, Miller C et al.. Identification and characterization of murine alternatively spliced tissue factor.  J Thromb Haemost. 2006;  4 158-167
  • 12 Yu J L, Rak J W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells.  J Thromb Haemost. 2004;  2 2065-2067
  • 13 Grimstad I A, Prydz H. Thromboplastin release,but not content,correlates with spontaneous metastasis of cancer cells.  Int J Cancer. 1988;  41 427-431
  • 14 Milsom C, Anderson G M, Weitz J I, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells.  J Thromb Haemost. 2007;  5 2550-2552
  • 15 Sahni A, Simpson-Haidaris P J, Sahni S K, Vaday G G, Francis C W. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2).  J Thromb Haemost. 2008;  6 176-183
  • 16 Coughlin S R. Thrombin signalling and protease-activated receptors.  Nature. 2000;  407 258-264
  • 17 D'Andrea M R, Derian C K, Santulli R J, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.  Am J Pathol. 2001;  158 2031-2041
  • 18 Smadja D M, Bieche I, Uzan G et al.. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system.  Arterioscler Thromb Vasc Biol. 2005;  25 2321-2327
  • 19 Kisucka J, Butterfield C E, Duda D G et al.. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.  Proc Natl Acad Sci U S A. 2006;  103 855-860
  • 20 Camerer E, Qazi A A, Duong D N, Cornelissen I, Advincula R, Coughlin S R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.  Blood. 2004;  104 397-401
  • 21 Rao L V, Pendurthi U R. Tissue factor-factor VIIa signaling.  Arterioscler Thromb Vasc Biol. 2005;  25 47-56
  • 22 Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer.  Arterioscler Thromb Vasc Biol. 2005;  25 1545-1550
  • 23 Ahamed J, Versteeg H H, Kerver M et al.. Disulfide isomerization switches tissue factor from coagulation to cell signaling.  Proc Natl Acad Sci U S A. 2006;  103 13932-13937
  • 24 Mueller B M, Reisfeld R A, Edgington T S, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.  Proc Natl Acad Sci U S A. 1992;  89 11832-11836
  • 25 Nierodzik M L, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype.  Cancer Cell. 2006;  10 355-362
  • 26 Mueller B M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis.  J Clin Invest. 1998;  101 1372-1378
  • 27 Bromberg M E, Konigsberg W H, Madison J F, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.  Proc Natl Acad Sci U S A. 1995;  92 8205-8209
  • 28 Palumbo J S, Talmage K E, Massari J V et al.. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms.  Blood. 2007;  110 133-141
  • 29 Wang H, Fu W, Im J H et al.. Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis.  J Cell Biol. 2004;  164 935-941
  • 30 Radjabi A R, Sawada K, Jagadeeswaran S et al.. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and {beta}1-integrin on the cell surface.  J Biol Chem. 2008;  283 2822-2834
  • 31 Shi X, Gangadharan B, Brass L F, Ruf W, Mueller B M. Protease-activated receptor 1 (PAR1) and PAR2 contribute to tumor cell motility and metastasis.  Mol Cancer Res. 2004;  2 395-402
  • 32 Camerer E, Duong D N, Hamilton J R, Coughlin S R. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency.  Blood. 2004;  103 152-154
  • 33 Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Crosstalk of integrin α3β1 and tissue factor in cell migration.  Mol Biol Cell. 2004;  15 4416-4425
  • 34 Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain.  J Biol Chem. 2004;  279 23038-23044
  • 35 Ott I, Weigand B, Michl R et al.. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38.  Circulation. 2005;  111 349-355
  • 36 Ahamed J, Niessen F, Kurokawa T et al.. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia.  Blood. 2007;  109 5251-5259
  • 37 Siegbahn A, Johnell M, Sørensen B B, Petersen L C, Heldin C H. Regulation of chemotaxis by the cytoplasmic domain of tissue factor.  Thromb Haemost. 2005;  93 27-34
  • 38 Versteeg H H, Schaffner F, Kerver M et al.. Inhibition of tissue factor signaling suppresses tumor growth.  Blood. 2008;  111 190-199
  • 39 Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling.  J Thromb Haemost. 2003;  1 1495-1503
  • 40 Morris D R, Ding Y, Ricks T K, Gullapalli A, Wolfe B L, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.  Cancer Res. 2006;  66 307-314
  • 41 Hjortoe G M, Petersen L C, Albrektsen T et al.. Tissue factor-factor VIIa specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated via PAR-2 and results in increased cell migration.  Blood. 2004;  103 3029-3037
  • 42 Zoudilova M, Kumar P, Ge L, Wang P, Bokoch G M, DeFea K A. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2.  J Biol Chem. 2007;  282 20634-20646
  • 43 Koizume S, Jin M-S, Miyagi E et al.. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.  Cancer Res. 2006;  66 9453-9460
  • 44 Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells.  Cancer Res. 2001;  61 5933-5940
  • 45 Sorensen B B, Rao L VM, Tornehave D, Gammeltoft S, Petersen L C. Anti-apoptotic effect of coagulation factor VIIa.  Blood. 2003;  102 1708-1715
  • 46 Versteeg H H, Arnold S C, Richel D J, Peppelenbosch M P. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis.  Oncogene. 2004;  23 410-417
  • 47 Pendurthi U R, Allen K E, Ezban M, Rao L VM. Factor VIIa and thrombin induce the expression of cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa tissue factor-induced signal transduction.  J Biol Chem. 2000;  275 14632-14641
  • 48 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression.  J Biol Chem. 2000;  275 6580-6585
  • 49 Liu Y, Mueller B M. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways.  Biochem Biophys Res Commun. 2006;  344 1263-1270
  • 50 Albrektsen T, Sorensen B B, Hjortoe G M, Fleckner J, Rao L VM, Petersen L C. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.  J Thromb Haemost. 2007;  5 1588-1597
  • 51 Uusitalo-Jarvinen H, Kurokawa T, Mueller B M, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.  Arterioscler Thromb Vasc Biol. 2007;  27 1456-1462
  • 52 Palumbo J S, Kombrinck K W, Drew A F et al.. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.  Blood. 2000;  96 3302-3309
  • 53 Belting M, Dorrell M I, Sandgren S et al.. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.  Nat Med. 2004;  10 502-509
  • 54 Griffin C T, Srinavasan Y, Zheng Y-W, Huang W, Coughlin S R. A role for thrombin receptor signaling in endothelial cells during embryonic development.  Science. 2001;  293 1666-1670
  • 55 Caunt M, Huang Y Q, Brooks P C, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.  J Thromb Haemost. 2003;  1 2097-2102
  • 56 Haralabopoulos G C, Grant D S, Kleinman H K, Maragoudakis M E. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo.  Am J Physiol. 1997;  273 C239-C245
  • 57 Zania P, Kritikou S, Flordellis C S, Maragoudakis M E, Tsopanoglou N E. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1 (PAR-1): association with endothelial cell growth suppression and induction of apoptosis.  J Pharmacol Exp Ther. 2006;  318 246-254
  • 58 Colognato R, Slupsky J R, Jendrach M, Burysek L, Syrovets T, Simmet T. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells.  Blood. 2003;  102 2645-2652
  • 59 Fields R C, Schoenecker J G, Hart J P, Hoffman M R, Pizzo S V, Lawson J H. Protease-activated receptor-2 signaling triggers dendritic cell development.  Am J Pathol. 2003;  162 1817-1822
  • 60 Csernok E, Ai M, Gross W L et al.. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway.  Blood. 2006;  107 4440-4448
  • 61 Rafii D C, Psaila B, Butler J, Jin D K, Lyden D. Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells.  Arterioscler Thromb Vasc Biol. 2008;  28 217-222
  • 62 Zhang Y, Deng Y, Luther T et al.. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest. 1994;  94 1320-1327
  • 63 Kakkar A K, Chinswangwatanakul V, Lemoine N R, Tebbutt S, Williamson R CN. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma.  Br J Surg. 1999;  86 890-894
  • 64 Abe K, Shoji M, Chen J et al.. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.  Proc Natl Acad Sci U S A. 1999;  96 8663-8668
  • 65 Yu J L, May L, Lhotak V et al.. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.  Blood. 2005;  105 1734-1741
  • 66 Yin Y J, Salah Z, Grisaru-Granovsky S et al.. Human protease-activated receptor 1 expression in malignant epithelia. A role in invasiveness.  Arterioscler Thromb Vasc Biol. 2003;  23 940-944
  • 67 Martin C B, Mahon G, Klinger M et al.. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways.  Oncogene. 2001;  20 1953-1963
  • 68 Yin Y J, Katz V, Salah Z et al.. Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization.  Cancer Res. 2006;  66 5224-5233
  • 69 Gupta G P, Nguyen D X, Chiang A C et al.. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.  Nature. 2007;  446 765-770
  • 70 Caunt M, Hu L, Tang T, Brooks P C, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.  Cancer Res. 2006;  66 4125-4132
  • 71 Miller G J, Bauer K A, Howarth D J, Cooper J A, Humphries S E, Rosenberg R D. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway.  J Thromb Haemost. 2004;  2 2107-2114
  • 72 Zacharski L R, Henderson W G, Rickles F R et al.. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate.  Cancer. 1984;  53 2046-2052
  • 73 Klerk C P, Smorenburg S M, Otten H M et al.. The effect of low molecular weight heparin on survival in patients with advanced malignancy.  J Clin Oncol. 2005;  23 2130-2135
  • 74 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin. therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS).  J Clin Oncol. 2004;  22 1944-1948
  • 75 Lee A YY, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23 2123-2129
  • 76 Hembrough T A, Swartz G M, Papathanassiu A et al.. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.  Cancer Res. 2003;  63 2997-3000

Wolfram RufM.D. 

Department of Immunology, SP258, The Scripps Research Institute

10550 North Torrey Pines Road, La Jolla, CA 92037

Email: ruf@scripps.edu